Aude G. Chapuis


Appointments and Affiliations

Fred Hutchinson Cancer Research Center
Clinical Research Division
Assistant Member, Appointed: 2014
University of Washington
School of Medicine
Assistant Professor, Appointed: 2014
The Fred Hutch Bone Marrow Transplant Program
Seattle Cancer Care Alliance (SCCA)
Attending Physician, Appointed: 2010
Professional Headshot of Aude G. Chapuis

Mailing Address

1100 Fairview Ave N
P.O. Box 19024
Seattle, Washington 98109-1024


Phone: (206) 667-4369
Fax: (206) 667-7983


2002: Medical Doctorate in Medicine/Immunology, Faculty of Medicine, Lausanne University (Lausanne, Switzerland)
1997: Swiss Federal Medical Diploma in Medicine, Faculty of Medicine, Lausanne University (Lausanne, Switzerland)

Previous Positions

2010–2014: Research Associate, Fred Hutchinson Cancer Research Center and Acting Instructor, University of Washington
2007–2010: Medical Oncology Fellowship, Fred Hutchinson Cancer Research Center and University of Washington
2001–2003: Medical Resident, Department of Internal Medicine, Lausanne University Hospital (Lausanne, Switzerland)
2000–2001: Medical Resident, Department of Internal Medicine, Cadolles Cantonal Hospital (Neuchatel, Switzerland)
2003–2007: Postdoctoral Research Fellow, Fred Hutchinson Cancer Research Center and University of Washington
1998–1999: Pre-doctoral Research Fellow and Medical Resident, Laboratory of AIDS Immunopathogenesis, Lausanne University Hospital (Lausanne, Switzerland)


American Association for Cancer Research, Associate Member

Research Interests

Dr. Chapuis is a Medical Oncologist and an adult hematopoietic stem cell transplant (HCT) physician with a strong background in Immunology and adoptive T-cell transfer studies in humans. She has tracked the fate of and characterized antigen-specific T cells adoptively transferred in patients with HIV, melanoma, Merkel Cell carcinoma (MCC) and leukemia. She has extensive experience in preparing and maintaining successful investigator-initiated Investigational Investigational New Drug (IND) applications for the FDA regarding adoptive therapy trials. She recently participated in the identification and generation of a native high-affinity WT1-specific T cell receptor (TCR), optimized the clinically applicable Good Manufacturing Practice (GMP) methods for lentiviral transduction of virus-specific T cells with the WT1-specific TCR; she is the Sponsor of the FDA approved IND as well as the co-Principal Investigator of an adoptive clinical trial utilizing genetically modified CD8+ T cell transduced with a WT1-specific TCR to target leukemias in pre- and post-transplant settings, as well as non-small cell lung cancer.
Dr. Chapuis’ laboratory continues developing novel ways to modulate the immune system to target cancer:
  1. They perform critical immune-monitoring during adoptive transfer studies involving autologous antigen-specific cells or TCR-transduced cells in the settings of melanoma, NSCLC and leukemias - the focus is on understanding the factors associated with successful adoptive transfer of antigen-specific T cells targeting viral or tumor antigens.
  2. Dr. Chapuis and her team are developing strategies to improve the quality of T-cell infusion products by modulating selection and culture systems and the host environment by infusing the immune cells along with immune-modulatory agents such as checkpoint inhibitors. Dr. Chapuis is the Principal Investigator of a trial that combines anti-PDL1 (avelumab) with Merkel cell polyoma virus (MCPyV)-specific T cells for the treatment of patients with metastatic MCC.
  3. The Chapuis lab is working on novel ways to validate TCRs that bind specific target antigens. Currently the lab is focused on developing high-throughput strategies to identify and generate native high-affinity TCRs from multiple donors to target ‘cancer-testis antigens,’ including MAGE antigens, that are expressed on various cancers but not on normal tissues except for male germ cells in adults.
  4. The team is also working to target other tumor-associated antigens with engineered TCRs that confer function to both CD8+ and CD4+ T cells, as opposed to more typical CD8+ only protocols. These reagents will ultimately be tested in patients with both solid and liquid tumors. In particular, MAGE-family antigen-targeting TCRs are being developed for patients with lung and breast cancers.
  5. The main focus of the lab is on developing and testing new strategies to establish long-term functional anti-tumor T-cell responses in humans.

Recent Publications

Schmitt TM, Stromnes IM, Chapuis AG, Greenberg PD.  2015.  New Strategies in Engineering T-cell Receptor Gene-Modified T Cells to More Effectively Target Malignancies.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(23):5191-5197. Abstract

Coming Soon: New Profiles System!

In preparation for the launch of our new profiles system, we are freezing updates to these profiles. If you have any questions, please email

Researcher Profiles


Related Websites


Scientific Divisions